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Demographic and clinical characteristics of patients
Gender
Age
(years) Qp/Qs
VSD size
(mm)
Aneurysm
inlet size
(mm) Device
Patient 1 Male 26 2.2 4 5 PmVSD
occluder
Patient 2 Female 18 2 8 18 Muscular
VSD
occluder
Patient 3 Male 36 1.6 5 19 Muscular
VSD
occluder
Patient 4 Male 36 1.6 4 19 ADO-II
Patient 5 Male 42 1.7 8 15 Muscular
VSD
occluder
Patient 6 Male 62 2 8 9 PmVSD
occluder
Patient 7 Male 21 1.7 9 13 ADO-I
Patient 8 Female 49 1.6 3 8 PmVSD
occluder
Patient 9 Female 49 1.7 3 5 Muscular
VSD
occluder
Patient
10
Male 23 2.1 5 11 ADO-II
Patient
11
Female 36 1.7 8 15 Muscular
VSD
occluder
VSD: ventricular septal defect ADO: Amplatzer Duct Occluder
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Scontacted by phone at 1, 3 and 6 month. The primary study endpoint was cardio-
vascular death.
Results: A total of 248 patients from 10 centers in various geographical areas were
randomized: 125 to EHFP and 123 to RC at the time of hospital discharge. The mean age
of all patients was 60.813.8 years. The patients were predominantly men (73%) with
NYHAclass II - IV heart failure symptomswho had amean ejection fraction of 26.8 7.3
%. Demographic characteristics, including age, sex, laboratory evaluations and assess-
ments of cardiac function, and functional capacity were equivalent in both treatment
groups. Use of pharmacologic therapy at baseline in the patients demonstrated compli-
ance with guidelines recommended therapy. Six-month cardiovascular mortality was
signiﬁcantly higher in the RC group (p<0.05). At baseline 60% of patients in EHFP and
61% RC were in NYHA Class III and IV; at 6-month follow up only 12% in EHFP and
32% in RC were in NYHA Class III and IV. The mean number of hospitalization was
0.580.91 in EHFP and 0.641.05 in RC (p¼NS) and the mean number of emergency
roomvisitswere 0.841.15 and1.211.47, respectively at 6-month follow-up (p<0.05).
Conclusion: Our study results showed that an enhanced education lead by a cardiol-
ogist and a phone follow up program signiﬁcantly reduced the cardiovascular deaths
and number of emergency room visit within 6 months after discharge in HF patients.
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Introduction: The middle-term results of VSD closure using different devices in our
clinic are presented.
Patients and Methods: Patients undergoing transcatheter VSD closure in our clinic
between April 2007 and June 2013 were reviewed. Defects were closed in cases with
a large VSD on echocardiography, left chamber hypertrophy and hemodynamically
a Qp/Qs>1.5 and/or reversible pulmonary hypertension. In perimembranous VSD the
left disk of the occluder was placed on the left of the septum in the absence of
aneurysm. If an aneurysm was present, the left disk was placed inside it, to reduce the
risk of AV block.
Results:Median age of the patients was 8 (range, 10 months - 55 years); their average
follow-up was 3720 months and average Qp/Qs 2.00.63. Average VSD diameter
was 913 mm (3-20). Implantation was successful in 74 (92.5%) of the 80 patients.
Of these, 51 had perimembranous and 23 muscular defects. For cases with peri-
membranous defects, an eccentric Amplatzer perimembranous VSD device was
placed in 18, a Cardioﬁx muscular VSD device in 17, an Amplatzer or Cardioﬁx duct
occluder in 9, an Amplatzer muscular VSD device in 3, a Lifetech muscular VSD
device in another 3 and an ADOII device in one patient. The device was placed within
the aneurysm tissue in 18 cases. As for muscular VSD, Cardioﬁx muscular VSD
device was used in 18 patients, an Amplatzer muscular VSD device in 2, a Lifetech
muscular VSD in another 2 and a Cardioﬁx ASD occluder in one patient. Complete
occlusion immediately post-intervention was achieved in 52% (39/74), 70% (52/74)
on the next day and 85% (63/74) at the 6-month follow-up. The residual defect ratio
was signiﬁcantly higher where the device had been placed inside the aneurysm
(p<0.05). One patient had a reversible complete AV block and another one experi-
enced hemolysis, no other major complications were observed. One patient underwent
open surgery for a signiﬁcant residual defect. During follow-up, two patient had de
novo presentation of non-progressive, minimal aortic insufﬁciency.
Conclusion: VSD occlusion by different devices is safe and efﬁcacious in selected
patients. While placement of the device inside the aneurysm increases the proportion
of residual shunt, it is believed that it may reduce the risk of AV block, the most feared
complication.
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Introduction: Ventricular septal defects (VSD) are the most common congenital
heart disease. Of these defects 80% involves the membranous septum. With theJACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAintroduction of eccentric perimembranous VSD (PmVSD) occluder devices, percu-
taneous closure of PmVSDs has become an accepted alternative to surgical closure.
However, closure of PmVSDs associated with septal aneurysms is more challenging.
We report our experience of device closure of PmVSD associated with septal
aneurysm.
Material-Methods: Between 2008 and 2012, percutaneous closure of PmVSD
associated with a septal aneurysm was attempted in 11 patients in our institution. The
indication for VSD closure was the presence of hemodynamically signiﬁcant PmVSD
demonstrated by cardiac catheterisation (Qp/Qs > 1.5). We used 2 methods to occlude
PmVSD associated with septal aneurysm: 1) to close the defect at the left ventricular
opening of the aneurysm by anchoring the left disc of the occluder at the the inlet
portion of the aneurysm and compressing the aneurysm and the defect between the left
and the right discs of the device; 2) to close the defect at the outlet by anchoring the
left disc of the device at the left side of the outlet portion of the aneurysm. We
preferred to use the ﬁrst method when the aneursym was small and there is adequate
distance from the aortic valve. The patients were followed up at 1st, 3rd, 6th and 12th
months after the closure procedure by TTE and ECG.
Results: Mean age of the patients was 36.21.3 and 64% were male. The demo-
graphic and clinical characteristics of patients are shown in table 1. The average
diameter of the VSD was 5.92.4 mm by angiography. One patient had 2 defects
within the aneurysm and 1 patient had dextrocardia. Large aneurysm (the inlet portion
of the aneurysm > 10 mm) was present in 7 patients. The procedure was successful in
all patients. We used Amplatzer PmVSD occluder device in 3 patients, Amplatzer
Muscular VSD occluder device in 5 patients, Amplatzer Duct occluder-I (ADO-I) in 1
patient and ADO-II device in 2 patients. We prefered to occlude the defect by the
ﬁrst method in 4 patients who had a small aneurysm and PmVSD occluder was used in
3 cases and a muscular VSD occluder device was implanted in 1 patient. Second
method was prefered in 7 patients who had larger aneurysms. A trivial residual shunt
was detected by ventriculography in 4 patients immediately after the procedure.
Complete closure was observed by transthoracic echocardiography in all patients at
the time of discharge. The patients were followed-up at mean of 221.9 months.
There was no device or procedure related complications at the acute setting or mid-
term follow-up.
Conclusion: Percutaneous closure of PmVSDs associated with aneurysm is more
challenging than simple defects. The selection of the device type and size should be
made according to the conﬁguration and size of the aneurysm and the defect.LS C75
